Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies - Top-Institutions - MDSpire

Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies

  • By

  • Sigrun Einarsdottir

  • Stephanie Lobaugh

  • Danny Luan

  • Marina Gomez-Llobell

  • Padmapriya Subramanian

  • Sean Devlin

  • David Chung

  • Parastoo B. Dahi

  • Lorenzo Falchi

  • Sergio Giralt

  • Heather Landau

  • Alexander M. Lesokhin

  • Richard Lin

  • Jennifer Lue

  • Sham Mailankody

  • M. Lia Palomba

  • Jae H. Park

  • Gilles Salles

  • Michael Scordo

  • Silvia Escribano-Serrat

  • Jaime Sanz

  • Kai Rejeski

  • Roni Shouval

  • Saad Usmani

  • Miguel-Angel Perales

  • Gunjan Shah

  • Zainab Shahid

  • July 2, 2025

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology/Oncology
    • Immunology
    • Cellular Therapy

  • #2

    Fred Hutchinson Cancer Center
    Fred Hutchinson Cancer Center

    Seattle, WA

    Key Differentiators

    • Hematology/Oncology
    • Immunology
    • Cellular Therapy

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Hematology/Oncology
    • Immunology
    • Cellular Therapy

  • #4

    National Cancer Institute (NCI)
    National Cancer Institute (NCI)

    Bethesda, MD

    Key Differentiators

    • Hematology/Oncology
    • Immunology
    • Cellular Therapy

  • #5

    University of Pennsylvania Perelman School of Medicine
    University of Pennsylvania Perelman School of Medicine

    Philadelphia, PA

    Key Differentiators

    • Hematology/Oncology
    • Immunology
    • Cellular Therapy

Original Source(s)

Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies

  • by Sigrun Einarsdottir, Stephanie Lobaugh, Danny Luan, Marina Gomez-Llobell, Padmapriya Subramanian, Sean Devlin, David Chung, Parastoo B. Dahi, Lorenzo Falchi, Sergio Giralt, Heather Landau, Alexander M. Lesokhin, Richard Lin, Jennifer Lue, Sham Mailankody, M. Lia Palomba, Jae H. Park, Gilles Salles, Michael Scordo, Silvia Escribano-Serrat, Jaime Sanz, Kai Rejeski, Roni Shouval, Saad Usmani, Miguel-Angel Perales, Gunjan Shah, Zainab Shahid

  • July 2, 2025

Related Content

Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review

Country-Specific Data and Priorities for Pertussis in Latin America: Recent Findings From the Global Pertussis Initiative

SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma